AbbVie proclaimed that it has finalized a deal with Samsung Bioepis and their joint venture partner Biogen Inc. that would deter U.S. competition of their biosimilar version to blockbuster drug Humira (Adalimumab) until 2023. This would mark the second deal AbbVie has made in the past year, trying to protect patents on their favorable drug, Humira.
AbbVie’s Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis. Atopic dermatitis, a chronic inflammatory skin disease, is characterized by skin erosion, oozing and crusting, redness, intense itching (pruritus) and dry skin.12 Symptoms can appear as a rash on the skin, or the skin may become thickened and leathery.
AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain. The US Food and Drug Administration (FDA) has granted priority review to AbbVie’s investigational candidate, elagolix, for the management of endometriosis with associated pain. Endometriosis is characterised by long-term pelvic pain and caused by tissue growth outside of the uterus.
